Table 1. Baseline clinical and laboratory characteristics of all studies included in the meta-analysis.
| Study | Country | Cases number (n) | Sex (M/F) | Ages | BMI (kg/m2) | Normal+ chronic hepatitis/liver fibrosis+ cirrhosis | Child (A/B) | TNM (I+II/III+IV) | Differentiation (well+ moderate/poor) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S | NS | S | NS | S | NS | S | NS | S | NS | S | NS | S | NS | S | NS | |||||||||
| Harimoto, 2013 | Japan | 75 | 111 | 50/25 | 95/16 | 67.0 | 66.0 | 20.5 | 24 | 32/43 | 55/56 | 68/7 | 107/4 | 49/26 | 75/36 | 59/16 | 87/24 | |||||||
| Voron, 2015 | France | 59 | 50 | 53/6 | 39/11 | 64.55 | 58.25 | 24.62 | 26.85 | 27/32 | 19/31 | NR | NR | NR | NR | 47/12 | 48/2 | |||||||
| Yabusaki, 2016 | Japan | 89 | 106 | 57/32 | 100/6 | 66.2 | 63.8 | 21.8 | 24.3 | NR | NR | 81/8 | 101/5 | 64/25 | 68/38 | 84/5 | 98/7 | |||||||
| Takagi, 2016 | Japan | 118 | 136 | 93/25 | 114/22 | 68.6 | 63.1 | 22.0 | 25.2 | NR | NR | NR | NR | 59/59 | 79/57 | 99/19 | 120/16 | |||||||
| Hamaguchi, 2019 | Japan | 84 | 522 | 55/7 | 312/91 | 71.6 | 67.0 | 20.6 | 23.8 | 37/25 | 189/214 | 57/5 | 364/39 | 29/33 | 218/185 | 48/13 | 296/95 | |||||||
| Kroh, 2019 | Germany | 33 | 37 | 21/12 | 28/9 | 66.97 | 68.43 | 25.29 | 27.85 | 15/18 | 12/25 | NR | NR | NR | NR | NR | NR | |||||||
S, sarcopenia; NS, non-sarcopenia; M, men; F, female; NR, not reported.